Folic Acid Supplementation and Spontaneous Preterm Birth: Adding Grist to the Mill?

Leonie Callaway1,2, Paul B. Colditz2,3, Nicholas M. Fisk2,3*

1 School of Medicine, The University of Queensland, Brisbane, Queensland, Australia, 2 Royal Brisbane & Women’s Hospital, Herston, Queensland, Australia, 3 University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia

Preterm birth is increasing, and complicates 12% of deliveries in the United States. It is the dominant cause of neonatal mortality. Preterm birth also accounts for one in three children with vision impairment, and almost half with cerebral palsy [1]. Babies born weighing under 2,500 g are at heightened risk in adulthood of diabetes and cardiovascular disease [1]. These short- and long-term sequelae make the prevention of preterm birth a public health priority.

**Therapeutic Nihilism in Preterm Labor**

Although some preterm births are indicated for maternal or fetal complications, most are spontaneous. Yet there is no licensed tocolytic agent available in the US to treat early-onset contractions, no treatment for threatened preterm labor that improves neonatal outcome, and no new class of drug under development [2]. In the face of such therapeutic nihilism, attention has turned instead to prophylaxis. There is encouraging evidence that prophylactic progesterone in women at increased risk (shortened cervix, previous history) reduces the incidence of very preterm birth [3,4]. Enthusiasm for this approach has been dampened by two setbacks. First, progesterone does not work in all pregnancies at risk (specifically twins). Second, 17-hydroxyprogesterone caproate recently failed to win approval from the US Food and Drug Administration due to safety concerns about fetal death rates in monkeys and humans [5,6].

**Prophylactic Folic Acid: Newfound Benefit of an Old Approach?**

Poor periconceptional nutrition is implicated in idiopathic preterm labor in both animal models and human studies. As with the progesterone story, there is renewed interest in decades-old suggestions that folic acid may reduce preterm birth [7–9]. Because of poor compliance with recommendations to take periconceptional folate supplements to prevent neural tube defects (NTDs), more than 50 countries have already introduced mandatory wheat flour fortification [10–12]. In California, this was associated with a modest reduction in low birthweight and preterm birth [13].

In this issue of *PLoS Medicine*, Radek Bukowski and colleagues report that additional voluntary folic acid supplementation was associated with a major reduction in very preterm births, those most at risk of adverse outcomes [14]. Women taking supplements for at least one year before conception had a 70% reduction in spontaneous preterm birth between 20–28 weeks, and a 50% reduction between 28–32 weeks, when compared to those with no additional supplementation. Long-term compared to no supplementation was associated with a reduction in the risk of spontaneous preterm birth before 32 weeks from one in 154 to one in 423.

Given the multiple causes of preterm labor, is this degree of hazard reduction plausible [15]? Biologically, the authors point to anti-inflammatory mechanisms. On the one hand, infection is implicated in only a minority of preterm births, but on the other, infection is found increasingly at earlier gestational ages, such as those suggested to benefit most in this study. In keeping with this mechanism, no association was seen with non-infective phenomena, such as indicated preterm birth or disorders of placentaion.

**Linked Research Article**

This Perspective discusses the following new study published in *PLoS Medicine*:

Bukowski R, Malone FD, Porter FT, Nyberg DA, Comstock CH, et al. (2009) Preconceptional folic acid supplementation and the risk of spontaneous preterm birth: A cohort study. *PLoS Med* 6(5): e1000061. doi:10.1371/journal.pmed.1000061

In an analysis of a cohort of pregnant women, Radek Bukowski and colleagues describe an association between taking folic acid supplements and a reduction in the risk of preterm birth.

---

**Provenance:** Commissioned; not externally peer reviewed

**Funding:** The authors received no specific funding for this article.

**Competing Interests:** LC declares that she has no competing interests related to this Perspective. PBC was involved with the Micronutrient Initiative in lobbying for flour fortification in Australia and New Zealand. NMF was a member of the UK Advisory Board of Ferring Pharmaceuticals until 2007, has received recent travel funds from Ferring International, the Royal College of Obstetricians and Gynaecologists, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, and the North American Fetal Treatment Network, and acts as an expert witness in medicolegal litigation in obstetrics. Between 1996–2002, he was a member of a UK lobby group (chair Prof. N. Wald) to enrich commercial flour to prevent spina bifida.

**Abbreviations:** NTD, neural tube defect.

* E-mail: n.fisk@uq.edu.au

---

**Citation:** Callaway L, Colditz PB, Fisk NM (2009) Folic Acid Supplementation and Spontaneous Preterm Birth: Adding Grist to the Mill? *PLoS Med* 6(5): e1000077. doi:10.1371/journal.pmed.1000077

**Published:** May 12, 2009

**Copyright:** © 2009 Callaway et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Methodologically, the study has several strengths, and is unlikely to be replicated. It is based on a huge dataset, with prospective recording of dietary supplements and potential confounders, and gestational age determined accurately on first trimester ultrasound. Those born preterm because of intervention were appropriately censored.

Nevertheless, there remains need for caution. This was a secondary analysis of a Down syndrome screening study, and so information on folic acid dose, formulation (with or without other supplements), and daily compliance is incomplete. In relation to numerators, there were only 16 births at under 32 weeks in those on long-term supplements. One unanswered question is whether women on folic acid for at least one year took a larger dose more diligently, resulting in higher folate levels at conception compared to women taking shorter-term supplements (women taking supplements were better educated, white, non-smoking, and different to the remaining women on nearly every measured parameter). Indeed, controlling for confounders negated the significance of any effect of less than one year’s supplementation. Long-term consumption of preconceptional folic acid supplements in other countries might suggest a subfertility/planning pregnancy, consume daily only of mandatory flour fortification, but countries might suggest a subfertility/trial. Long-term consumption of preconceptional folic acid reduces spontaneous preterm birth in mothers with a previous preterm birth, ideally with high-dose and low-dose arms compared to standard care to dissect out dose versus duration effects.

Obstetric Implications

These tantalizing findings add further impetus to the study of preconceptional factors and interventions that impact on duration of pregnancy. The ultimate evidence as to whether folic acid prevents spontaneous preterm birth will require a randomized controlled trial, but conducting such a trial may prove challenging on several fronts. First, there are robust reasons to encourage all women to take folic acid. Second, one third of the world already has mandatory folic acid fortification [11]. Third are the ethical difficulties with a control group, although these might be surmounted in geographical areas where prepregnancy supplementation is not yet supported. One practical way forward would be a randomized controlled trial of ongoing folic acid supplementation in mothers with a previous preterm birth, ideally with high-dose and low-dose arms compared to standard care to dissect out dose versus duration effects.

Public Health Policy: Too Little, Too Late?

There is increasing evidence that recommended supplementation levels are inadequate to optimize pregnancy outcome. Studies from North and South America show that low-level fortification of flour prevents at most only 40% of NTDs, because such fortification provides only a quarter of the recommended daily intake [16,17]. Bukowski and colleagues’ study confirms that fewer than 20% of women follow recommendations for additional folate, while in settings without mandatory fortification of flour, such as most of Europe, as few as 3% of women take the recommended 400 μg dose in the three months prior to conception [10]. Higher daily doses result in higher folate levels, and there is a continuous dose–response relationship between early pregnancy folate levels and NTD prevention [18]. Compelling arguments have been made to increase mandatory flour fortification levels 2–4 fold and pre-pregnancy folic acid tablets to 4–5 mg per day, aiming to prevent around 85% of NTDs [17]. There is little downside, now that earlier concerns about folic acid unmasking vitamin B12 deficiency appear resolved, and the evidence on whether folate supplementation increases twinning remains inconclusive [19,20].

Does Bukowski and colleagues’ study provide additional impetus for an increase in the recommended dose of folic acid [19]? No, that would be premature in the absence of intervention studies to substantiate folic acid reducing very preterm birth. This is particularly important given the experience with cardiovascular disease, where epidemiological evidence suggested protective effects of folic acid supplementation that were not borne out in subsequent randomized trials [21]. In the interim, super-supplementation can be justified entirely on the basis that it would double the number of NTDs prevented.

Author Contributions

ICMJE criteria for authorship read and met: LC NMF PBC. Wrote the first draft of the paper: LC NMF. Contributed to the writing of the paper: PBC.

References

1. Spong CY (2009) Preterm birth: An enigma and a priority. Obstet Gynecol 113: 770–771.
2. Fisk NM, Atun R (2008) Market failure and the poverty of new drugs in maternal health. PLoS Med 5: e22. doi:10.1371/journal.pmed.0050022.
3. Fonseca ER, Celik E, Parra M, Singh M, Nicolasles KH (2007) Progestrone and the risk of preterm birth among women with a short cervix. N Engl J Med 357: 462–469.
4. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Shiabi B, et al. (2003) Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348: 2379–2385.
5. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, et al. (2007) A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 357: 454–461.
6. Dodd JM, Flenady VJ, Cincotta R, Crowther CA (2008) Progesterone for the prevention of preterm birth: A systematic review. Obstet Gynecol 112: 127–134.
7. Bloomfield FH, Oliver MH, Hawkins P, Campbell M, Phillips DJ, et al. (2003) A periconceptional nutritional origin for noninfectious preterm birth. Science 300: 606.
8. Baumslag N, Edeleanu T, Menj J (1970) Reduction of incidence of prematurity by folic acid supplementation in pregnancy. Br Med J 1: 16–17.
9. Blot I, Papiernik E, Kaltwasser JP, Werner E, Tchernia G (2007) Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357: 462–469.
10. Inskip HM, Crozier SR, Godfrey KM, Berland SE, Cooper C, et al. (2009) Women’s compliance with nutrition and lifestyle recommendations before pregnancy: General population cohort study. BMJ 338: 481.
11. Centers for Disease Control and Prevention (2009) Recommendations on wheat and maize flour fortification. Meeting report: Interim consensus statement. Available: http://www.who.int/nutrition/publications/micronutrients/wheat_maize_fort.pdf. Accessed 16 April 2009.
12. Wald NJ, Law MR, Morris JK, Wald DS (2001) Quantifying the effect of folic acid. Lancet 358: 2069–2073.
13. Daly LE, Kirke PN, Mollby A, Weir DG, Scott JM (1993) Folate levels and neural tube
19. Wald NJ (2004) Folic acid and the prevention of neural-tube defects. N Engl J Med 350: 101–103.

20. Muggli EE, Halliday JL (2007) Folic acid and risk of twinning: A systematic review of the recent literature, July 1994 to July 2006. Med J Aust 186: 243–248.

21. Lonn E (2008) Homocysteine-lowering B vitamin therapy in cardiovascular prevention—Wrong again? JAMA 299: 2086–2087.